NCT05795517View on ClinicalTrials.gov

Study of HSK31679 in Subjects With Hypercholesterolemia With Nonalcoholic Fatty Liver Disease（NAFLD）

PHASE2CompletedINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

April 26, 2023

Primary Completion Date

February 20, 2024

Study Completion Date

March 1, 2024

Conditions
Hypercholesterolemia
Interventions
DRUG

HSK31679 low dose

HSK31679 low dose and placebo of HSK31679 ，QD，oral，Day1 to week 12

DRUG

HSK31679 medium dose

HSK31679 medium dose and placebo of HSK31679 ，QD，oral，Day1 to week 12

DRUG

HSK31679 high dose

HSK31679 high dose and placebo of HSK31679 ，QD，oral，Day1 to week 12

DRUG

Placebo

placebo ，QD，oral，Day1 to week 12

DRUG

Ezetimibe 10mg

Ezetimibe 10mg+placebo of HSK31679 ，QD，oral，Day1 to week 12

Trial Locations (1)

Unknown

Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing

All Listed Sponsors
lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY